OVERVIEW

ImmunoBiosciences, Inc has proprietary rights to a novel Immune Complex Vaccine (ICV) technology, which is broadly applicable to both human and veterinary vaccines. The ICV technology has been validated commercially with USDA licensed poultry vaccines in worldwide poultry markets and further validated in numerous proof of principle studies. ImmunoBiosciences, Inc. commenced operations in 2004 to capitalize on the unique opportunity to expand the success of the novel ICV technology from poultry to other animal species and humans. ICV technology has also been referred to in scientific publications and patents as viral neutralizing factor technology or virus-antibody complex vaccine technology.

The ICV technology is a proprietary technology that has the potential to improve the safety and efficacy of vaccines containing live, attenuated, or killed viruses and bacteria. The ICV technology utilizes neutralizing antibodies in the form of either specific hyper-immune antiserum or monoclonal antibodies that are mixed with viruses or bacteria at the appropriate predetermined ratio to form an antigen-antibody immune complex vaccine that can be used as a safer and more efficacious vaccine. The technology has been successfully tested using several viral and bacterial test systems in multiple species and shown improved efficacy with both veterinary and human vaccine candidates.

Advantages of the technology include improved safety without loss of immunogenicity, lower effective dosing schedules (single versus multiple dosing), protection even in the face of maternal antibody, long lasting immunity, and a potential for broad, cross-reactive protection.

The human and veterinary vaccines markets are currently large, $12 billion and $4 billion, respectively and the human vaccine market is expected to reach $20 billion annually by 2015. The ICV technology has the potential to help catalyze this growth.

We are located in Raleigh, North Carolina in North Carolina State University's Centennial Campus, an advanced technology community for industry, University, and government partners. Our management team has extensive experience in development of both veterinary and human vaccine products.

ImmunoBiosciences commenced operations in 2004 and completed its seed round of financing in December 2005, followed by a successful secondary round in January 2008. ImmunoBiosciences is privately owned.